Xiamen Kingdomway Group Co banner

Xiamen Kingdomway Group Co
SZSE:002626

Watchlist Manager
Xiamen Kingdomway Group Co Logo
Xiamen Kingdomway Group Co
SZSE:002626
Watchlist
Price: 15.21 CNY -3.92% Market Closed
Market Cap: ¥9.3B

EV/IC

1.8
Current
20%
Cheaper
vs 3-y average of 2.3

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1.8
=
Enterprise Value
¥10B
/
Invested Capital
¥4.8B

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1.8
=
Enterprise Value
¥10B
/
Invested Capital
¥4.8B

Valuation Scenarios

Xiamen Kingdomway Group Co is trading below its 3-year average

If EV/IC returns to its 3-Year Average (2.3), the stock would be worth ¥19.06 (25% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+39%
Average Upside
21%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 1.8 ¥15.21
0%
3-Year Average 2.3 ¥19.06
+25%
5-Year Average 2.5 ¥21.15
+39%
Industry Average 2 ¥17.25
+13%
Country Average 1.9 ¥16.27
+7%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close
Market Cap EV/IC P/E
CN
Xiamen Kingdomway Group Co
SZSE:002626
9.3B CNY 1.8 19.2
US
Eli Lilly and Co
NYSE:LLY
908.9B USD 8.9 36
US
Johnson & Johnson
NYSE:JNJ
547.1B USD 3.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 2.9 20.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 3.7 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 2.9 20.7
US
Merck & Co Inc
NYSE:MRK
277.6B USD 2.6 31.1
IE
Endo International PLC
LSE:0Y5F
244.4B USD 56 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 2.7 12.1
US
Pfizer Inc
NYSE:PFE
149.7B USD 1 19.3
US
Bristol-Myers Squibb Co
NYSE:BMY
118.9B USD -9.1 4 516.9
P/E Multiple
Earnings Growth PEG
CN
Xiamen Kingdomway Group Co
SZSE:002626
Average P/E: 472.9
19.2
20%
1
US
Eli Lilly and Co
NYSE:LLY
36
32%
1.1
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
31.1
14%
2.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.3
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
4 516.9
648%
7

Market Distribution

In line with most companies in China
Percentile
48th
Based on 7 566 companies
48th percentile
1.8
Low
0 — 1.1
Typical Range
1.1 — 3.4
High
3.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.1
Median 1.9
70th Percentile 3.4
Max 1 129 391.6

Xiamen Kingdomway Group Co
Glance View

Market Cap
9.3B CNY
Industry
Pharmaceuticals

Xiamen Kingdomway Group Co., rooted firmly in the bustling industrial city of Xiamen, China, has carved a unique niche within the health and nutrition sector. The company's journey is emblematic of strategic diversification and industry foresight. Originating as a manufacturer of vital active pharmaceutical ingredients, Kingdomway quickly harnessed its expertise and infrastructure to expand into the production of vitamins, nutritional supplements, and health-care products. This strategic expansion allowed the company to capture various segments of the health market, not only focusing on pharmaceuticals but also venturing into consumer health goods. Integral to its business model is leveraging advanced biotechnology and robust research capabilities, ensuring consistent innovation and the delivery of high-quality products that cater to global health and wellness demands. The financial engine of Xiamen Kingdomway turns on the adept integration of rigorous research and development with a vast, diversified distribution network. The company has built a vertically integrated supply chain, which provides a competitive edge in controlling production costs while maintaining stringent quality standards. Through strategic alliances and investments in key markets worldwide, Kingdomway enhances its footprint and taps into the expanding consumer base eager for health and wellness solutions. Its significant revenue streams flow from both domestic sales and international exports, with an adept marketing strategy that positions its offerings in numerous global markets. By emphasizing continuous improvement and customer-centric innovation, Xiamen Kingdomway ensures a strong positioning amid the dynamic landscape of the wellness industry.

Intrinsic Value
23.62 CNY
Undervaluation 36%
Intrinsic Value
Price ¥15.21
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett